4296-73-5 Usage
Description
(2Z)-4-(hydroxyamino)-4-oxobut-2-enoic acid, also known as 4-Hydroxyamino-4-oxo-2-butenoic acid, is a chemical compound with the molecular formula C4H5NO4. It serves as an intermediate in the biosynthesis of the amino acid methionine and is integral to the one-carbon metabolism pathway. This molecule is significant in the regulation of sulfur-containing amino acids and is involved in the conversion of homocysteine to methionine. Furthermore, it contributes to the synthesis of S-adenosylmethionine, which is a key molecule in numerous biochemical reactions. (2Z)-4-(hydroxyamino)-4-oxobut-2-enoic acid is essential for the overall metabolism of sulfur-containing amino acids in living organisms.
Uses
Used in Pharmaceutical Industry:
(2Z)-4-(hydroxyamino)-4-oxobut-2-enoic acid is used as an intermediate for the production of methionine, a crucial amino acid in the pharmaceutical industry. Its role in the one-carbon metabolism pathway and sulfur-containing amino acid regulation makes it a vital component in the synthesis of various pharmaceutical compounds.
Used in Biochemical Research:
In the field of biochemical research, (2Z)-4-(hydroxyamino)-4-oxobut-2-enoic acid is utilized as a key molecule for studying the metabolic pathways involving sulfur-containing amino acids. Its involvement in the conversion of homocysteine to methionine and the synthesis of S-adenosylmethionine provides valuable insights into the regulation of these essential biochemical processes.
Used in Nutritional Supplements:
(2Z)-4-(hydroxyamino)-4-oxobut-2-enoic acid can be used as a component in the development of nutritional supplements that focus on supporting sulfur-containing amino acid metabolism and overall cellular health.
Used in Agricultural Industry:
In the agricultural industry, (2Z)-4-(hydroxyamino)-4-oxobut-2-enoic acid may be employed in the development of additives or supplements for livestock to enhance their sulfur-containing amino acid metabolism, thereby improving their overall health and productivity.
Check Digit Verification of cas no
The CAS Registry Mumber 4296-73-5 includes 7 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 4 digits, 4,2,9 and 6 respectively; the second part has 2 digits, 7 and 3 respectively.
Calculate Digit Verification of CAS Registry Number 4296-73:
(6*4)+(5*2)+(4*9)+(3*6)+(2*7)+(1*3)=105
105 % 10 = 5
So 4296-73-5 is a valid CAS Registry Number.
4296-73-5Relevant articles and documents
-
Endres,Epstein
, p. 1497,1498 (1959)
-
DICARBONIC ACID DERIVATIVES, METASTASIS INHIBITORS AND AGENTS INCREASING CHEMOTHERAPEUTIC ACTIVITY OF ANTI-TUMOR PREPARATIONS, METHOD FOR ENHANCING THE EFFICIENCY OF CYTOSTATICS AND METASTASIS PROCESS INHIBITING METHOD
-
Page/Page column 2, (2008/06/13)
The invention relates to dicarbonic acid derivatives and concerns dicarbonic acid monooxydamines and dioxydamides, which are physiologically active substances and can be used as low-toxic and non-toxic agents for enhancing the anti-tumor and anti-metastasis effects of known cytostatics (cyclophosphane and cisplatin) in cytostatic chemotherapy of tumors. The object of the present invention is to broaden the assortment of agents affecting a live organism in order to enhance anti-tumor and anti-metastasis effects of known cytostatics. This object is resolved by the properties of dicarbonic acid monooxydamines and dioxydamides. The essence of the invention consists in that dicarbonic acid derivatives, the formulas of which are presented in the specification, are proposed as agents for enhancing anti-tumor and anti-metastasis effects of cytostatics. The claimed compounds can be used in medical practice as low-toxic agents for enhancing anti-tumor and anti-metastasis effects of known cytostatics with a simultaneous 4-fold reduction of the therapeutic dose of cytostatics. The use of the proposed compounds in a combination with cisplatin at the minimum doses makes it possible to completely inhibit the metastasis process in experimental B-16 melanoma. Furthermore, the use of the proposed compounds at the minimum doses in a combination with the minimum doses of cytostatics (when neither of the preparations alone exhibitsefficacy) makes it possible to obtain a high therapeutic effect in treating leukemias (survival of animals with P-388 leukemia in the test group is 100%).
